Phase II Trial of Single Agent Ipilimumab (MDX-010 Anti CTLA-4) for Subjects With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Phase: PHASE2
Conditions: Pancreatic Cancer
Sponsor: Bristol-Myers Squibb

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v

1.0
Approved
930036949
1.0
v